How Many Uninsured Are in the Coverage Gap and How Many Could be Eligible if All States Adopted the Medicaid Expansion? - KFF

TorontoToronto public health officials say they are seeing a rise in mpox infections in the city and are urging eligible residents to get vaccinated. Public health unit says 14 cases confirmed since September, but risk to public remains lowThe Canadian Press · Posted: Oct 05, 2026 2:31 PM EDT | Last Updated: October 5Listen to this articleEstimated 1 minuteThe audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Toronto Public Health says 14 cases of mpox have been confirmed since September, and wastewater monitoring by the Public Health Agency of Canada has also 'consistently detected mpox' in the city. (Graham Hughes/The Canadian Press)Toronto public health officials say they are seeing a rise in mpox infections in the city and are urging eligible residents to get vaccinated. Toronto Public Health says 14 cases of the viral illness have been confirmed since September, and wastewater monitoring by the Public Health Agency of Canada has also "consistently detected mpox" in the city.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.